Chondracanthus chamissoi

Other Names

chicorea de marchicoria de marChondracanthus glomeratusChondroclonium chamissoicochayuyoGigartina chamissoiGigartina glomeratamocochosea chicorySphaerococcus chamissoiyuyo

Synopsis

Chondracanthus chamissoi: A Comprehensive Reference

1. Identity, Taxonomy, and Natural Source

Chondracanthus chamissoi (C.Agardh) Kützing, 1843, is a marine red macroalga (seaweed) belonging to the phylum Rhodophyta. Its full taxonomic placement is: kingdom Plantae, phylum Rhodophyta, class Florideophyceae, order Gigartinales, family Gigartinaceae, genus Chondracanthus. Its original basionym is Sphaerococcus chamissoi C.Agardh, 1820, and it has been placed at various times under the synonyms Gigartina chamissoi (C.Agardh) J.Agardh, 1842, and Chondroclonium chamissoi (C.Agardh) Kützing, 1849, both now considered unaccepted names. The accepted binomial, established by Friedrich Traugott Kützing in 1843, remains the standard in current literature and is validated by the World Register of Marine Species (WoRMS) and AlgaeBase.

Chondracanthus chamissoi, known in Peru as "yuyo" or "mococho," is distributed in South America from Paita, Peru (5°S) to Ancud, Chile (42°S). Specimens identified morphologically as C. chamissoi in South Korea, Japan, and France have also proven to be C. chamissoi when phylogenetically evaluated with mitochondrial and plastidial DNA sequences, meaning the known distribution of the species is no longer considered endemic to Peru and Chile.

Members of the genus Chondracanthus (Rhodophyta, Gigartinales) inhabit the shores of both hemispheres and have been used for decades in some countries as raw material for carrageenan extraction and in some cases destined for human consumption. The broad morphological variation of Chondracanthus species makes necessary the use of molecular tools for species delimitation, which has led to the re-grouping and geographic re-distribution of some entities.

Common Names

Yuyo or mococho — Peru
Sea Chicory — English-language supplement markets
"Peruvian Irish Moss" or "Pacific Irish Moss" — marketing terminology in North American and European supplement trade

It is important to note that the name "Irish Moss" properly refers to Chondrus crispus, a different Atlantic species. C. chamissoi and Chondrus crispus are different species: C. chamissoi is a Pacific red seaweed, while true Irish Moss (Chondrus crispus) is native to the Atlantic. They have similar gelling properties but different nutritional profiles.

Common Dosage Forms and Preparations

In both traditional and modern contexts, C. chamissoi is encountered in several forms:

Fresh thallus: It is consumed in a fresh state, serving as an accompaniment in typical coastal dishes or as a main ingredient in salads.
Dehydrated / dried whole thallus: Its fresh and dehydrated form has enjoyed growing demand in Asian countries, where C. chamissoi is consumed in soups and salads.
Seaweed powder: The whole dried thallus is ground to a fine powder used in smoothies, capsules, teas, or as a culinary thickener.
Carrageenan extract: Most of the biomass (60–100% of all C. chamissoi exports) is destined for the extraction of carrageenans, polysaccharides with multiple applications in the formulation of various foods due to their binding, emulsifier, and thickener properties.
Capsules: Encapsulated whole-thallus powder is commercially available as a dietary supplement.
Pressurized liquid extracts: Used in experimental and analytical settings to concentrate polyphenols and bioactive compounds.

2. Traditional and Historical Use

This seaweed appears to have been part of the Peruvian diet since pre-Hispanic times, as indicated by archaeobotanical records from the Nazca and Paracas cultures and by the algal representation on ceramics of the Moche culture. These records situate human use firmly in the pre-Columbian era along the Pacific coast of South America, making C. chamissoi one of the few macroalgae with documented archaeological evidence of consumption predating European contact in the Americas.

C. chamissoi has been consumed since pre-Hispanic times and is considered a fundamental ingredient in several dishes, such as the traditional Peruvian ceviche, "picantes" (spicy dishes), and soups. Since C. chamissoi is used for human consumption as a gourmet ingredient in the traditional Peruvian dish ceviche, investment in cultivation for this purpose may be more viable than for the carrageenan industry.

Beyond its culinary role, coastal communities have historically ascribed therapeutic properties to the alga. Traditional preparations included fresh consumption or decoctions, and the alga was attributed uses across several health domains:

General vitality and energy: C. chamissoi, known as "sea moss" or "yuyo," has a history of use in traditional medicine, particularly in Peru and other parts of South America, where it has been consumed as a food source and used for its purported health benefits, including as a general tonic to support vitality and reduce fatigue.
Digestive complaints: Folk remedies often recommended preparations of C. chamissoi for digestive ailments, including constipation and gastric discomfort, attributing its effectiveness to the mucilaginous texture and high fiber content.
Respiratory complaints: In some communities, decoctions or infusions made from the dried seaweed were given to alleviate symptoms of colds or respiratory issues, capitalizing on the seaweed's natural richness in iodine and other trace elements.
Immune support and inflammation: Folk remedies recommended preparations for digestive ailments; the seaweed was also used to fortify the immune system and was valued for its anti-inflammatory and antioxidant properties.

The remaining exported biomass (at most 40%) is mostly destined for China, Japan, and Taiwan, where it is traditionally used in soups and salads. This extends documented food use of the species beyond the Americas into East Asian food cultures, where it arrived through the trade in dehydrated seaweed.

3. Key Constituents and Active Compounds

3.1 Proximate Nutritional Composition

A 2024 peer-reviewed characterization study (Gamero-Vega et al., published in Plant Foods for Human Nutrition) provided detailed compositional data for dried C. chamissoi collected from the Peruvian coast. The control dried seaweed sample presented 20.2 ± 0.16 g/100 g dry weight (dw) of proteins, 20.0 ± 0.61 g/100 g dw of ash, and 56.6 ± 0.08 g/100 g dw of total dietary fiber. In addition, the control sample presented 1.6 ± 0.07 mg gallic acid equivalents (GAE)/g of total polyphenol content and 2.4 ± 0.30 mM Trolox mg/g of antioxidant capacity.

The species' international demand has been attributed to its rich composition of carbohydrates (<60%), proteins (17–44%), and lipids (<45%), as well as its high carrageenan, amino acid, and unsaturated fatty acid concentrations. The relatively wide ranges reflect variation by season, geographic origin, life-cycle phase (gametophyte vs. tetrasporophyte), and processing method.

3.2 Carrageenans (Sulfated Polysaccharides)

The single most commercially and biologically significant class of compounds in C. chamissoi is its carrageenan content. From a scientific perspective, C. chamissoi is recognized for its high levels of carrageenan, a sulfated polysaccharide that serves as a dietary fiber and is widely used as a natural food additive for its gelling, thickening, and stabilizing properties.

The mean carrageenan contents of C. chamissoi ranged from 15.2 to 42.1% dry weight. Higher yields were observed in gametophytes than in tetrasporophytes, and in samples collected in summer than in winter. This substantial seasonal and life-stage variability has direct implications for the reproducibility of preparations used as dietary supplements.

Carrageenans from members of the Gigartinaceae family, including C. chamissoi, are classified structurally as kappa/iota-carrageenan-type or lambda-carrageenan-type depending on the life-cycle phase of the thallus. Carrageenan is a natural compound derived from red seaweeds, well known from Chondrus, Gigartina, and various Eucheuma species, all in Rhodophyceae. These sulfated polysaccharides carry anionic charges along the polymer backbone, which underlies many of their proposed biological activities including interaction with proteins, lipids, and pathogens.

3.3 Polyphenols and Bromophenols

Within the bioactive compounds present in seaweeds, some polyphenols have high antioxidant power. The polyphenols found in seaweeds are not the same as those present in terrestrial vegetables. Red and green seaweeds contain bromophenols, which are complex structures of different combinations of brominated phenolic compounds.

In a 2024 pressurized liquid extraction study using C. chamissoi from Peru, optimal extraction at 150°C and 30% ethanol yielded a high polyphenol content of 2.04 mg GAE/g dw and antioxidant capacity (IC₅₀: 7.46 mg/mL, ORAC: 148.98 μmol TE/g dw). These values are influenced by extraction conditions; the effect of water–ethanol mixtures (0, 15, and 30%; v/v) at high temperatures (90, 120, and 150°C) on the polyphenol content, antioxidant capacity, and polyphenol profile of C. chamissoi showed that an increase in temperature and ethanol had a positive effect on antioxidant compounds.

3.4 Minerals and Micronutrients

Nutritional analyses have shown that this seaweed is a good source of essential nutrients, including calcium, magnesium, potassium, and certain B vitamins. The notably high ash content (~20% dw) reflects the concentration of marine minerals accumulated from the surrounding seawater. The species is also documented as a source of iodine, iron, vitamin C, vitamin K, and trace elements including manganese and selenium, consistent with its marine origin and the general mineral profile of edible red seaweeds from the Gigartinales order.

3.5 Dietary Fiber and Functional Properties

The exceptionally high total dietary fiber content (56.6% dw in the control sample) contributes directly to the seaweed's functional food properties. Regarding functional properties, C. chamissoi presents 17.6 ± 0.15 g/g of water-holding capacity (WHC), 2.4 ± 0.78 g/g of oil-holding capacity (OHC), and 9.8 ± 0.75 mL/g of swelling capacity (SC). These parameters are technologically relevant for use in food formulation and may contribute to satiety effects when consumed.

Seaweeds are recognized as prebiotics due to their polysaccharides and dietary fiber, which are resistant to digestion in the upper intestine, undergoing fermentation in the lower gut, where they are selectively utilized by host commensal bacteria.

4. Scientific Evidence by Area of Use

4.1 Antioxidant Activity

Evidence level: Preliminary — in vitro and compositional studies only.

The 2024 PubMed-indexed characterization study confirmed that C. chamissoi seaweed is characterized by its nutritional composition, total polyphenols, antioxidant capacity, and functional properties including water-holding capacity, oil-holding capacity, and swelling capacity. The study conducted by Gamero-Vega et al. (2024) applied two independent antioxidant capacity assays to dried samples subjected to different thermal treatments. Boiling before dehydration causes a significant decrease (p < 0.05) in total polyphenols and increases carbohydrates, whereas steaming before dehydration causes a significant (p < 0.05) increase in carbohydrates without significantly altering the concentration of total polyphenols. This finding has direct practical implications for how the ingredient should be processed to preserve antioxidant activity.

A separate 2024 extraction optimization study from the Universidad Nacional de Moquegua (Peru) confirmed that pressurized liquid extraction at 150°C and 30% ethanol achieved the highest polyphenol yield and antioxidant capacity from C. chamissoi samples collected from Ilo, Peru. The study characterized the polyphenol profile and inhibition of α-amylase, but these measurements were conducted entirely in vitro. No human or animal trials measuring systemic antioxidant outcomes from C. chamissoi supplementation have been published as of the available literature.

4.2 Alpha-Amylase Inhibition and Potential Glycemic Modulation

Evidence level: Preliminary — in vitro only.

The 2024 pressurized liquid extraction study (Huamán-Castilla et al., Molecules) simultaneously evaluated the capacity of C. chamissoi polyphenol extracts to inhibit α-amylase, an enzyme central to starch digestion and postprandial glycemia. The study evaluated water–ethanol mixtures at high temperatures on the polyphenol content, antioxidant capacity, and polyphenol profile of C. chamissoi during pressurized liquid extraction; an increase in temperature and ethanol had a positive effect on antioxidant compounds, and the best processing conditions established at 150°C and 30% ethanol allowed extraction of a high polyphenol content (2.04 mg GAE/g dw) and high antioxidant capacity (IC₅₀: 7.46 mg/mL, ORAC: 148.98 μmol TE/g dw). The α-amylase inhibitory activity was assessed entirely in vitro. No clinical trials investigating glycemic or antidiabetic outcomes in humans have been conducted with C. chamissoi as a specific intervention.

4.3 Anti-inflammatory Potential

Evidence level: Traditional use; mechanistic rationale only; no direct clinical studies identified.

C. chamissoi, known as "yuyo," is a red seaweed traditionally consumed in Peru and other parts of South America. Its use in treating or supporting inflammation is primarily rooted in folk medicine rather than in robust scientific validation. There are limited phytochemical activity studies conducted in vitro or in animal models. Direct clinical or preclinical studies specifically examining C. chamissoi for anti-inflammatory effects are lacking as of June 2024.

The mechanistic basis most frequently invoked involves the sulfated polysaccharides (particularly carrageenan-type structures) and bromophenol-class polyphenols found in the alga. Research in related red seaweed species has documented anti-inflammatory signaling effects in cell-culture models, but these findings cannot be directly extrapolated to whole-food or supplement-grade C. chamissoi without species-specific studies.

4.4 Gut Health and Prebiotic Potential

Evidence level: Animal study (broiler model); no human trials specific to this species.

A 2025 study (published in a peer-reviewed journal and indexed on ResearchGate) evaluated the effects of dietary supplementation with C. chamissoi on broiler chickens. C. chamissoi is high in carbohydrates, fiber, polyphenols, and amino acids, and has been shown to have antifungal activities; the aim of this study was to assess the effects of C. chamissoi supplementation on broiler chickens, specifically evaluating its effects on intestinal morphology, growth performance, and cecal microbial community. Marine macroalgae has the potential to improve growth performance in broiler chickens due to the presence of bioactive compounds.

While this non-human study is the most direct experimental evidence for gut-modulating effects, results in poultry cannot be directly applied to human physiology. There are no well-controlled clinical studies directly assessing the effects of C. chamissoi on human digestive health. Most of the available evidence is anecdotal or extrapolated from general knowledge about seaweed fibers and their impact on digestion.

4.5 Immunomodulatory and Antimicrobial Potential

Evidence level: Preliminary — in vitro data for related compounds; species-specific human data absent.

Seaweed is a natural source of sulfated polysaccharides and polyphenols that have been shown to have antimicrobial and antiviral properties. C. chamissoi has been shown to have antifungal activities, based on a 2023 study by Torres et al. The antifungal finding adds to a growing body of evidence on the antimicrobial potential of Gigartinales-family red seaweeds, but this work was conducted outside clinical conditions. No controlled human trials on immune outcomes have been published specifically for C. chamissoi.

4.6 Carrageenan: Food Industry and Biomedical Applications

Evidence level: Well-established for technological applications; biomedical effects of native whole-food carrageenan are under continued study.

Carrageenan extracted from C. chamissoi and related Gigartinales is a commercially established food hydrocolloid used globally in dairy products, meat processing, infant formula, and cosmetics. Carrageenan and related red-seaweed polysaccharides have been found to have anti-cancer activity by improving immunity and targeting key apoptotic molecules and therefore have been deemed potential chemotherapeutic or chemopreventive agents. However, this evidence comes from cell-line and animal research in other carrageenan-producing species; species-specific clinical trials with C. chamissoi-derived carrageenan in humans have not been published.

4.7 Overall Summary of Evidence Strength

Emerging research suggests that red seaweeds like C. chamissoi may exhibit antioxidant, anti-inflammatory, and immunomodulatory effects due to their unique bioactive compounds. While several in vitro and animal studies indicate potential health benefits such as cholesterol reduction, improved gut health, and support for immune function, well-designed human clinical trials specifically focused on C. chamissoi are still limited. This characterization by the research literature is accurate as of mid-2025: the entirety of direct evidence consists of compositional analyses, in vitro bioactivity assays, and a single non-human (poultry) supplementation study. No randomized controlled trials (RCTs) in human subjects have been published for any health outcome specifically attributed to C. chamissoi.

5. Body Systems and Health Areas Associated

Based on the published scientific and traditional literature, the following body systems are most frequently associated with C. chamissoi:

Digestive system: Via dietary fiber, prebiotic polysaccharides, and mucilaginous carrageenan fractions; traditionally used for constipation and gastric discomfort.
Thyroid: Due to naturally occurring iodine content. Iodine is an essential trace element for thyroid hormone synthesis.
Immune system: Proposed via immunomodulatory sulfated polysaccharides and antimicrobial compounds; primarily traditional and in vitro basis.
Antioxidant / oxidative stress: Via polyphenols and bromophenols; confirmed by compositional and in vitro assays.
Metabolic health (glycemia): Proposed via α-amylase inhibition by polyphenolic fractions; evidence is in vitro only.
Skin health: Traditional attribution; carrageenan is used in topical applications in the cosmetics industry, though direct evidence from C. chamissoi-specific products is not available in the peer-reviewed literature.

6. Commercial Cultivation and Supply Considerations

C. chamissoi is an edible red seaweed with a high hydrocolloid content and food industry demand; this situation has led to a decline in their populations, especially in Peru. Between 2015 and 2020, Peru experienced a remarkable surge in its seaweed exports, increasing by approximately 216%. In particular, this period saw a particularly noteworthy expansion in the export of red seaweed (C. chamissoi), which increased by about 140%, finding its primary markets in countries like China, Canada, and the United States, whose sales reached a value of approximately USD 5 million.

Since the Peruvian Government does not regulate the wild harvest of red seaweeds, cultivation of C. chamissoi was attempted in Peru in the early 2000s as an alternative to harvesting from natural beds and to minimize overharvesting. Cultivation efforts are scientifically important because higher values of gel strength and viscosity were found relative to harvests from natural beds and could enhance exports of the species.

7. Dosage Forms and Reported Dosages

There are no clinically established or pharmacopeial dosage recommendations for C. chamissoi as of the available peer-reviewed literature. The following dosage-relevant information is drawn strictly from published research:

Compositional and extraction studies: Laboratory studies used dried seaweed at quantities sufficient for analytical assays (e.g., mg/g dw for polyphenol analysis). The 2024 MDPI Molecules study employed pressurized liquid extraction parameters of 10 atm, single extraction cycle, 150°C, 30% ethanol, and 150% volume ratio to maximize bioactive yield.
Carrageenan content: Mean carrageenan contents ranged from 15.2 to 42.1% dry weight, meaning the amount of carrageenan delivered per gram of whole dried seaweed is highly variable and season/phase-dependent.
Thermal treatment effects: In boiling samples, the apparent nutrient retention factors for proteins, fat, and dietary fiber are 96%, 47%, and 74%, respectively. In the steaming sample, the values were 102%, 29%, and 92%. These data have direct implications for the dosing of processed versus raw preparations.
Animal study: The 2025 broiler supplementation study used C. chamissoi as a dietary additive, but specific dosage amounts per kilogram of feed were not recoverable from the available abstract text.

No human clinical trials have established a minimum effective dose, maximum tolerated dose, or daily reference intake for whole-food or extract-grade C. chamissoi.

8. Safety Considerations and Interactions

8.1 Iodine Content and Thyroid Risk

The most substantiated safety concern with habitual consumption of C. chamissoi and seaweeds generally is iodine-induced thyroid dysfunction. High iodine levels in some seaweed species are considered a human health concern, and excess intake can lead to thyroid disorders. The Scientific Committee for Food established a tolerable upper intake level (UL) for iodine intake, and as seaweed can contain high concentrations of iodine, occurrence data for iodine have been gathered under European regulatory recommendations. This concern is particularly relevant for individuals with pre-existing thyroid conditions (hyperthyroidism, hypothyroidism, Hashimoto's thyroiditis, or Graves' disease), for whom iodine intake must be carefully managed.

8.2 Heavy Metals and Contaminants

Like all edible seaweeds, C. chamissoi bioaccumulates trace elements from its marine environment. EFSA assessed the relevance of seaweed and halophyte consumption to the dietary exposure to heavy metals (arsenic, cadmium, lead, and mercury) and iodine intake in the European population. From seaweed consumption, exposure estimates for cadmium in adult 'consumers only' are within the range of previous exposure estimates considering the whole diet, while for inorganic arsenic and lead the exposure estimates represent between 10% and 30% of previous exposures from the whole diet for the adult population.

A study concluded that seaweed consumption by the general population would pose a low health risk for mercury, cadmium, and lead intake. For most of the population, there was no risk of excessive iodine and inorganic arsenic exposure if seaweed was consumed rarely. However, a more detailed consumption assessment was required for high-risk sub-groups, such as pregnant women, children, and individuals with thyroid dysfunction.

Seaweeds were also identified as important sources of total arsenic, which mainly refers, with some exceptions, to organic arsenic. Organic arsenic species (such as arsenosugars and arsenobetaines) are generally considered far less toxic than inorganic arsenic, but regulatory assessments continue to evaluate this distinction. EFSA has identified seaweeds as one of the food commodities with the highest concentration of cadmium, although no specific concerns were identified at typical consumption levels.

The heavy metal burden of any specific batch of C. chamissoi will depend on the geographic origin of the harvest site and the degree of environmental contamination at that site. This variability means that routine testing of commercial preparations is necessary to ensure consumer safety.

8.3 Heavy Metal Biosorption

Research has documented that C. chamissoi biomass is being investigated as an adsorbent for removing heavy metals from aqueous solutions. To date, C. chamissoi has been used for carrageenan production and removing heavy metals from aqueous solutions. This dual characteristic — the capacity to adsorb heavy metals — means that commercially sourced material from polluted harvesting zones may carry elevated metal loads relative to material from clean-water environments.

8.4 Potential Drug Interactions

No species-specific pharmacokinetic or drug-interaction studies have been published for C. chamissoi. However, based on its chemical composition, the following theoretical interactions are identified from the broader seaweed literature:

Anticoagulant/antiplatelet drugs: Sulfated polysaccharides structurally related to heparin may potentiate anticoagulant drugs. Evidence from cell-line studies on related Gigartinales species suggests potential anticoagulant properties of carrageenan fractions, but this has not been tested clinically with C. chamissoi.
Thyroid medications: High iodine intake from dietary seaweed can interfere with the dosing of levothyroxine and other thyroid medications, as well as with anti-thyroid drugs used in hyperthyroidism.
Antidiabetic medications: Theoretical interaction via α-amylase inhibition (slowing starch digestion), which could alter postprandial glucose responses; this effect has not been tested in humans.

8.5 Pregnancy and Special Populations

A more detailed consumption assessment is required for high-risk sub-groups, such as pregnant women, children, and individuals with thyroid dysfunction. The combination of potentially high iodine and arsenic content in seaweed products makes these populations a priority concern. No dedicated safety studies for C. chamissoi in pregnant women, nursing mothers, children, or immunocompromised individuals have been published.

8.6 Processing Effects on Safety Profile

Thermal processing affects both the nutritional and potential toxicological profile. Boiling before dehydration causes a significant decrease (p < 0.05) in total polyphenols and increases carbohydrates. Boiling also has the potential to leach water-soluble minerals and heavy metals into cooking water, which may incidentally reduce the heavy metal load of the consumed portion, though this has not been quantified specifically for C. chamissoi.

9. Research Gaps and Future Directions

The scientific literature on C. chamissoi as a dietary supplement is in an early stage relative to more extensively studied seaweeds such as Chondrus crispus, Ecklonia cava, or Undaria pinnatifida. Critical gaps include:

Absence of any human randomized controlled trials for any health outcome.
No established pharmacokinetic data (absorption, distribution, metabolism, excretion of key bioactives).
Lack of standardized carrageenan-type characterization (kappa vs. iota vs. lambda) in commercially available supplement preparations.
No systematic evaluation of the bioavailability of polyphenols, minerals, or carrageenan fractions from whole-food preparations in human subjects.
Absence of dose-response data for any biological outcome.
No toxicity or safety studies specific to C. chamissoi extract or powder in mammals.

References

Health Conditions

Health conditions that Chondracanthus chamissoi may help support.

No conditions available.

Body Systems

Body systems that Chondracanthus chamissoi may help support.

No body systems available.